Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
5
Blackpink's solo journeys: Complementary paths, not competition
-
6
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
7
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
8
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
9
Actor Song Joong-ki welcomes second child in Rome
-
10
Main opposition pushes to ease, not postpone, tax on crypto gains
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
[THE INVESTOR] Daewoong Pharmaceutical announced on Sept. 21 that its botulinum toxin Nabota has been granted approval in Mexico and India.
The South Korean pharmaceutical company aims to launch the formula in both countries by 2017. It will strengthen its presence in South America where its neurotoxin, commonly known as Botox injected for cosmetological applications, is already sold in six countries including Panama and Guatemala.
Nabota was introduced in South Korea in 2014 and the company has orders from more than 60 countries to supply the product worth 700 billion won (US$626.40 million) so far.
Daewoong, the country’s fourth largest pharmaceutical company, will seek approval from the US Food and Drug Administration within this year.
By Hwang You-mee (glamazon@heraldcorp.com)
The South Korean pharmaceutical company aims to launch the formula in both countries by 2017. It will strengthen its presence in South America where its neurotoxin, commonly known as Botox injected for cosmetological applications, is already sold in six countries including Panama and Guatemala.
Nabota was introduced in South Korea in 2014 and the company has orders from more than 60 countries to supply the product worth 700 billion won (US$626.40 million) so far.
Daewoong, the country’s fourth largest pharmaceutical company, will seek approval from the US Food and Drug Administration within this year.
By Hwang You-mee (glamazon@heraldcorp.com)
![[Today’s K-pop] Babymonster logs 100m views with ‘Drip’ music video](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/11/22/20241122050051_0.jpg&u=20241122172213)